For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Fat Mass and Obesity-Associated Gene (FTO) in Eating Disorders: Evidence for Association of the rs9939609 Obesity Risk Allele with Bulimia nervosa and Anorexia nervosaMüller T.D.a, b, # · Greene B.H.c, # · Bellodi L.d · Cavallini M.C.d · Cellini E.e · Di Bella D.d · Ehrlich S.f · Erzegovesi S.d · Estivill X.g · Fernández-Aranda F.h · Fichter M.i · Fleischhaker c.j · Scherag s.a · Gratacòs M.g · Grallert H.k · Herpertz-Dahlmann B.l · Herzog W.m · Illig T.k · Lehmkuhl U.f · Nacmias B.e · Ribasés M.g · Ricca V.e · Schäfer H.c · Scherag A.n · Sorbi S.e · Wichmann H.-E.k, o · Hebebrand J.a · Hinney A.a
aDepartment of Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg-Essen, Essen, bInstitute Diabetes and Obesity, German Research Center for Environmental Health, Helmholtz Zentrum München, Neuherberg, cInstitute of Medical Biometry and Epidemiology, Philipps-University, Marburg, Germany; dDepartment of Neuropsychiatric Sciences (DSNP), Fondazione Centro S. Raffaele del Monte Tabor, Milan, eDepartment of Neurology and Psychiatric Sciences, University of Florence, Florence, Italy, fDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Charité-Universitätsmedizin Berlin, Germany, gCiber en Epidemiología y Salud Pública (CIBERESP), Genes and Disease Programme, Center for Genomic Regulation (CRG-UPF), hCIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN) and Department of Psychiatry, University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain, iDepartment of Psychiatry, University of Munich, Munich, jDepartment of Child and Adolescent Psychiatry and Psychotherapy, University of Freiburg, Freiburg i.Br., kInstitute of Epidemiology, German Research Center for Environmental Health, Helmholtz Zentrum München, Neuherberg, lDepartment of Child and Adolescent Psychiatry and Psychotherapy, University Clinics, Technical University of Aachen, Aachen, mDepartment of Internal Medicine II, General Internal and Psychosomatic Medicine, University of Heidelberg, Heidelberg, nInstitute of Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, oInstitute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany Corresponding Author
Dr. Anke Hinney
Department of Child and Adolescent Psychiatry and Psychotherapy
University of Duisburg-Essen
Virchowstraße 174, 45147 Essen (Germany)
Objective: The common single nucleotide polymorphism (SNP) rs9939609 in the fat mass and obesity-associated gene (FTO) is associated with obesity. As genetic variants associated with weight regulation might also be implicated in the etiology of eating disorders, we evaluated whether SNP rs9939609 is associated with bulimia nervosa (BN) and anorexia nervosa (AN). Methods: Association of rs9939609 with BN and AN was assessed in 689 patients with AN, 477 patients with BN, 984 healthy non-population-based controls, and 3,951 population-based controls (KORA-S4). Based on the familial and premorbid occurrence of obesity in patients with BN, we hypothesized an association of the obesity risk A-allele with BN. Results: In accordance with our hypothesis, we observed evidence for association of the rs9939609 A-allele with BN when compared to the non-population-based controls (unadjusted odds ratio (OR) = 1.142, one-sided 95% confidence interval (CI) 1.001–∞; one-sided p = 0.049) and a trend in the population-based controls (OR = 1.124, one-sided 95% CI 0.932–∞; one-sided p = 0.056). Interestingly, compared to both control groups, we further detected a nominal association of the rs9939609 A-allele to AN (OR = 1.181, 95% CI 1.027–1.359, two-sided p = 0.020 or OR = 1.673, 95% CI 1.101–2.541, two-sided p = 0.015,). Conclusion: Our data suggest that the obesity-predisposing FTO allele might be relevant in both AN and BN.
© 2012 S. Karger GmbH, Freiburg
Several SNPs in the first intron of the ‘fat mass and obesity-associated´ (FTO) gene are strongly associated with obesity in young individuals [1,2] and in adults [2,3,4,5,6,7,8]. The most frequently described SNP in FTO associated with obesity is rs9939609, which is located 82.431kb downstream of ATG start codon of FTO. The association of rs9939609 with obesity was discovered by a genome-wide association study (GWAS) for type 2 diabetes mellitus  and subsequently was convincingly corroborated by numerous other studies including the first GWAS for early onset (extreme) obesity . Accordingly, since it was first described in 2007 , the obesity predisposing risk A-allele at rs9939609 has become one of the most solidly confirmed risk factors for polygenetic obesity worldwide . Homozygous carriers of the risk A-allele at rs9939609 weigh about 3 kg more and have a 1.67-fold increased odds of obesity compared to homozygous carriers of the T-allele . Whereas the association of rs9939609 with obesity is indisputable, uncertainty remains about the potential association of this variant with eating disorders such as anorexia nervosa (AN) [10,11] and bulimia nervosa (BN). We and others have previously hypothesized that genes relevant in weight regulation might also be relevant in eating disorders [12,13,14,15,16]. Premorbid overweight and obesity are common in patients with BN, and a familial loading with obesity has also been described [17,18]. In contrast, premorbid BMI in AN covers the whole BMI range , and a familial predisposition to obesity has not been reported. Accordingly, due to the frequently reported premorbid occurrence of obesity in patients with BN, we hypothesized an association of the rs9939609 A-allele with BN, whereas for AN we had no specific a priori hypothesis. Additionally, we hypothesized that the obesity risk allele at rs9939609 is associated with maximum BMI-SDS in patients with these eating disorders. To determine whether the rs9939609 obesity risk-allele is associated with BN or AN, we analyzed a total of 6,101 individuals from three European countries (Germany, Italy, and Spain).
The ascertainment strategy was previously described in detail [13,20,21]. Written informed consent was given by all participants and, in the case of minors, by their parents. All patients with eating disorders were diagnosed according to DSM-IV criteria . The study was approved by the Ethics Committees of the Universities of Marburg, Duisburg-Essen, Heidelberg, Freiburg i.Br., Berlin, Aachen, Milan, Florence, and Barcelona as well as the Helmholtz Center Munich and carried out according to the Declaration of Helsinki.
In total, the study comprises 6,101 individuals from three European countries (Germany, Italy, and Spain). They were recruited at the Departments of Child and Adolescent Psychiatry of the Universities of Marburg, Duisburg-Essen, Aachen or Freiburg i.Br., Germany (N = 805); the Charité Hospital Berlin, Germany (N = 200); the German Research Center for Environmental Health, Helmholtz Center Munich, Neuherberg, Germany (N = 3,951), the Medical Psychosomatic Clinic Roseneck, Germany (N = 90); the Department of Psychosomatic Medicine, University of Heidelberg, Germany (N = 48), the Eating Disorders Unit of the Department of Psychiatry, University Hospital of Bellvitge, Spain (N = 503); the Neurology Unit of the Department of Neurology and Psychiatric Sciences, University of Florence, Italy (N = 232); or at the Fondazione Centro San Raffaelle del Monte Tabor, Milan, Italy (N = 272). Anthropometric data of the study subjects are listed in table 1.
The German samples included 103 patients with BN and 348 (10 male) patients with AN; of these 297 (6 male) individuals had acute AN, and 51 (4 male) were recovered individuals from two long-term follow-up studies of AN [23,24]. The German controls included 692 non-population-based German normal-weight or lean healthy individuals. We chose to also include lean individuals as controls, as their BMI is similar to the BMI of patients with AN. Thus, a detected association should be attributable to AN rather than to low body weight. In this sample, all individuals with a current eating disorder, like AN or Eating Disorder not Otherwise Specified (EDNOS), as assessed by a short version of the Composite International Diagnostic Interview (CIDI), were excluded from the study. The CIDI questionnaire was kindly provided by Professor Wittchen. In addition, we further compared genotypes of AN and BN cases with a second control group that comprised of 3,935 individuals of a population-based cohort (Kooperative Gesundheitsforschung im Raum Augsburg, (KORA); i.e. Cooperative Health Research in the Region of Augsburg). The KORA sample is a representative study group of the population in the city and region of Augsburg (Bavaria, Germany) .
The Italian samples included 261 patients with AN and 243 patients with BN. Italian controls were not available. The Spanish samples included 80 patients with AN, 131 patients with BN, and 292 Spanish healthy non-population-based controls covering all weight categories (table 1). In total, the 689 patients with AN had a mean age of 21.83 ± 7.13 years and a mean BMI of 15.87 ± 2.77 kg/m2. The 477 patients with BN had a mean age of 25.10 ± 6.51 years and a mean BMI of 23.12 ± 5.17 kg/m2.
Genotyping: The FTO SNP rs9939609 was either genotyped using ARMS-PCR as described previously , by KASPAR genotyping technology (KBioscience, Hoddesdon, UK), or (in case of the KORA samples) by MassARRAY system using iPLEX™ Gold chemistry (Sequenom, San Diego, CA, USA) . PCR conditions and primer sequences can be obtained from the authors. For validity of genotypes, alleles were rated independently by at least two experienced individuals. Discrepancies were resolved unambiguously either by reaching consensus or by retyping. All missing calls (approximately 2% of all genotyped individuals) were successfully re-genotyped. To ensure validity of genotyping between the described methods, we genotyped rs9939609 twice in 93 individuals; the genotypes were identical.
Hardy-Weinberg equilibrium for all independent study groups was tested with an exact test . It is also noteworthy that the reported genotype and allele frequencies of SNP rs9939609 are very similar among samples of European origin, including those from Italy , Spain [29,30] and Germany [1,26]. As stratification is therefore negligible, previous studies for different phenotypes have assessed association of rs9939609 in combined samples of European origin [31,32]. Accordingly, the case-control analyses reported here were also initially analyzed, irrespective of their origin; subsequent analyses were stratified by country (with the exception of the Italian cases due to a lack of controls from the same country). This post-hoc stratification of the samples was performed after obtaining a nominally significant result at level α = 0.05 for the global test. The reasons for stratification were to explore the robustness of the association across subsamples and to analyze the association, as far as possible, in subsamples in which the possibility of population stratification is reduced. For this reason, odds ratio (OR) estimates and nominal p-values from each subsample are unadjusted for multiple testing and not intended to provide confirmatory evidence at the 0.05 significance level.
The maximum BMI-SDS values were calculated in both German children/adolescents and German adults for which maximum BMI values were available. The maximum lifetime BMI was assessed by standardized questionnaires upon patient assessment. The patients were asked for their highest lifetime body weight and the corresponding age. As we previously showed that body height does not alter considerably after 13 years of age , we used the measured height at referral for the maxixum BMI estimations. Based on the German age-related reference data [33,34], the degree of maximum lifetime BMI was then quantified with Cole’s least mean square method , which normalized the BMI taking gender and age into account, resulting in a standard deviation score (BMI-SDS).
For the case-control comparisons with regard to the obesity risk A-allele at rs9939609, we applied the Cochran-Armitage trend test and logistic regression without and with covariates BMI and age. For the outcome maximum BMI-SDS in BN and AN patients we applied Jonckheere’s non-parametric trend test. We used a (log-)linear genetic model. Consistent with our unidirectional hypothesis that obesity is a risk factor for BN, we decided to display one-sided p-values for BN and two-sided p-values for AN in the case-control comparisons, whereas we reported one-sided p-values for the assessment of maximum BMI-SDS. All reported p-values are nominal and not adjusted for multiple testing, and we applied a level α = 0.05 for each test.
For BN, 477 cases and 984 European non-population-based controls were estimated  to yield a power of >0.80 to detect a multiplicative genotype-relative risk (GRR) of 1.27 (assuming a minor allele frequency (MAF) of 0.4). For the comparison with the 3,951 population-based controls, power estimates were >0.80 for a multiplicative GRR of 1.24 (again assuming a MAF of 0.4). For AN, power estimates for 689 cases and 984 non-population-based controls were >0.80 for a multiplicative GRR of 1.24 and >0.80 for a multiplicative GRR of 1.20 compared to the 3,951 population-based controls (again assuming a MAF of 0.4).
The combined analysis of all patients with BN (n = 477) and all non-population-based controls (n = 984) revealed an association of the rs9939609 obesity risk-allele (A) with BN (the unadjusted effect size estimate for the risk allele was an OR of 1.142, one-sided 95% confidence interval (CI) 1.001–∞; one-sided p = 0.049, 95%; table 2). Even though not statistically significant, a similar trend was observed when comparing all patients with BN with the 3,951 individuals of the population-based KORA-S4 cohort (one-sided p = 0.056; table 1). This trend did not change after exclusion of the 9 male subjects (468 cases and 3,951 controls; OR: 1.120, one-sided 95% CI 0.999–∞; p = 0.052, data not shown).
We also compared the patients with BN with the 3,951 population-based controls in a logistic regression model. In the case of BN, the unadjusted OR was 1.124 (one-sided 95% CI 1.003–∞; one-sided p = 0.046) and adjustment for age and BMI led to OR = 1.120 (one-sided 95% CI 0.932–∞; one-sided p = 0.155). Thus, the results were similar to the initial association test based on the Cochran-Armitage trend test (one-sided p = 0.056; table 2). The analyses stratified by country revealed that this observation was also consistent across subgroups with the exception of the German subgroup where no trend for differences in allele frequencies was observable (table 2).
In patients with BN we, however, observed no association of the obesity-predisposing risk A-allele at rs9939609 with BMI-SDS (TT 0.214 ± 1.24, TA 0.406 ± 1.49, AA 0.753 ± 1.89; one-sided p = 0.094).
In the case-control analysis including all patients with AN (n = 689) and all non-population-based controls (n = 984), we unexpectedly observed a nominal association of the A-allele at rs9939609 with AN (unadjusted OR = 1.181, 95% CI 1.027–1.359, two-sided p = 0.020, table 3). This association was also seen after exclusion of all 29 male subjects (660 cases and 3,951 controls; OR: 1.176, 95% CI 1.021–1.354; two-sided p = 0.025; data not shown).
Again, we also compared the patients with AN with the 3,951 population-based individuals and observed an unadjusted OR = 1.176 (95% CI 1.044–1.326; two-sided p = 0.008) and age- and BMI-adjusted OR = 1.673 (95% CI 1.101–2.541; two-sided p = 0.016). Thus, the results for AN were also similar to the initial association test based on the Cochran-Armitage Test (two-sided p = 0.015; table 3). The stratified analyses revealed that this finding was robust across subsamples.
The maximum BMI-SDS values were available for 105 German patients with BN and 214 German patients with AN. However, the trend test comparing the maximum BMI-SDS values revealed no evidence for an association of the rs9939609 obesity risk A-allele with increased maximum BMI-SDS in patients with BN or AN (nominal p = 0.066 or p = 0.180; table 4).
Genetic variation (e.g. at rs9939609) in the FTO has repeatedly been shown to be associated with obesity [1,2,3,4,5,6,7,8]. Based on our results we argue that the gene might also be relevant for eating disorders. Increased rates of both premorbid and familial overweight and obesity have been described in patients with BN [17,18], whereas in patients with AN the premorbid BMI has been shown to cover the whole BMI distribution . Hence, we had the a priori directional hypothesis that the obesity risk allele is implicated in BN and tested accordingly. We observed a nominally significant association of the rs9939609 A-allele in 477 patients with BN compared to 984 non-population-based controls (one-sided p = 0.049). For AN we had no specific a priori hypothesis. Nevertheless, for 689 patients with AN compared to 984 non-population-based controls we observed evidence for an association of the FTO obesity risk allele with AN (two-sided p = 0.020). Eating disorders are typically characterized by diagnostic instability, migration between different subtypes, and even between different eating disorders [38,39]. However, whereas several studies consistently show that 25–30% of patients with eating disorder migrate from AN to BN, migration from BN to AN is less frequently described [39,40]. Therefore, it is unlikely that the observed association of the rs9939609 A-allele with AN can be explained by AN patients with a history of BN. However, one of the limitations of our study is that detailed amnesic information, especially regarding previous eating disorders as well as follow-up data, was not available. Furthermore, even though substantial evidence indicates that stratification is, due to the very similar allele frequencies of rs9939609 among Europeans [1,3,29,30], negligible, the lack of Italian controls as well as the lack of anthropometric characteristics for the Spanish controls are other limitations of this study. Noteworthy, excluding the 243 Italian BN cases from our analysis (and thus decreasing the sample size by 49.1% from 477 to 234 patients with BN) would yield a nominal one-sided p-value of 0.110 for the comparison of the remaining 234 European BN cases versus 984 non-population based controls (OR 1.137, one-sided 95% CI 0.957–∞) and a nominal one-sided p-value of 0.137 for the comparison with the 3,951 German population-based controls (OR 1.111, one-sided 95% CI 0.948–∞). Exclusion of the 261 Italian patients with AN (and thus decreasing the sample size by 37.9% from 689 to 428 patients with AN) would yield a nominal two-sided p-value of 0.083 for the comparison of the remaining 428 patients with AN versus the 984 European non-population based controls (OR 1.155; 95% CI 0.981–1.360) and a nominal two-sided p-value of 0.094 for the comparison with the 3,951 German population-based controls. As solid evidence indicates that there are no stratification effects of rs9939609 among samples from Italy, Spain and Germany, the observed loss of significance is likely to be attributable to the dramatic loss of statistical power. Accordingly, to maximize the statistical power we choose to keep the Italian samples in our analysis. However, further studies are warranted to independently confirm our results and to analyze if, and to what extent, the association of the FTO risk allele is dependent on the DSM-IV AN and BN subtypes and the transversion of AN into BN (and vice versa). Another interesting aspect is the possible confounding effect of the behavioral influences on BMI in AN and BN patients. Since low BMI possibly influenced by FTO alleles will make individuals with eating disorders more likely to be diagnosed and become cases, this could be one potential source of confounding due to BMI in our analyses.
Besides a recent publication on the absence of an association of genetic variation in FTO in a sample of 267 patients with AN and 1,636 population-based controls , three studies investigated the effect of FTO variants on eating behavior [41,42,43]. Whereas, after adjustment for age and BMI, no association was found between rs9939609 and energy expenditure , two studies indicated a BMI-independent association of the rs9939609 risk A-allele with increased energy intake [41,42] and decreased satiety . Similarly, our observed association of FTO with AN might be independent of the elevating effect of this variant on BMI as based on our regression analysis including BMI as a quantitative covariate. Alternatively, it is possible that both a weight-elevating effect of the risk A-allele and a modulation of eating behavior and satiety accounts for the observed associations. Noteworthy, a recent publication further reports no association of FTO variants with psychological and behavioral eating disorder phenotypes, such as anxiety, harm avoidance, novelty seeking, impulsivity, obsessionality, compulsivity, and concern over mistakes .
A subgroup of the German non-population-based controls was lean (BMI below the 15th BMI percentile) and might thus have biased our analyses due to the established association of rs9939609 with obesity. Hence, we added a comparison of AN and BN cases with 3,951 individuals of a German population-based cohort (KORA) and adjusted for BMI and age. These analyses supported the aforementioned findings. It is further noteworthy that within the 3,951 population-based controls we also observed a significant additive effect of the obesity risk A-allele for an increased BMI (mean BMI AA 27.67 ± 4.73, AT 27.25 ± 4.75 TT 27.00 ± 4.65, mean BMI increase per A-allele 0.321 ± 0.109; p = 0.0032). Noteworthy, this trend was robust after adjustment for age and gender (mean increase per A-allele 0.329 ± 0.104; p = 0.0016).
We also hypothesized that the risk allele (A) for obesity at rs9939609 is associated with maximum BMI-SDS in patients with BN or AN. Analyses of maximum BMI-SDS values of individuals carrying either one, two, or no risk A-allele at rs9939609 revealed, however, no association of the obesity risk A-allele with maximum BMI-SDS in patients with either BN or AN (one-sided p = 0.066 or 0.180).
In summary, we observed evidence for an association of the A-allele at rs9939609 with both AN and BN. In patients with AN, the association was robust after adjustment for BMI and age. While the observation for AN was unexpected, the observed association of the obesity-predisposing risk A-allele with BN is in line with previous findings [17,18]. As obesity is a risk factor for the development of BN, obesity risk alleles should be more frequent in patients with BN. We conclude that genetic variation in FTO might be implicated in the etiology of BN and AN. However, additional research is warranted to determine whether the risk allele has a direct, indirect, or synergistic effect on eating disorders. The trend observed for association with maximum BMI-SDS in patients with BN suggests that for this eating disorder the association is indirect or synergistic. To address this question, we also analyzed the effect of FTO alleles on BN after adjusting for age and maximum BMI. The caveat of this approach is, however, that many of the lean controls were recruited for low current BMI which is strongly correlated with the maximum BMI of these patients. To control for this bias we adjusted our data for current BMI, revealing a nonsignificant estimated effect from the FTO risk A-allele (OR 0.888, 95% CI 0.601–1.312; p = 0.552) and a significant effect from max BMI (OR 2.134, 95% CI: 1.779–2.560; p < 0.001), thus identifying that the effect of FTO on BN is indeed indirect.
This work was supported by grants from the German Federal Ministry of Education and Research (01KU0903 and 01GI0823, 01GV0623, 01GV060, 01GV0624, 01GV0602, 01GV0905; NGFN2: 01GS0482, 01GS0483; NGFNPlus: 01GS0820), the European Union (FP6 LSHMCT-2003–503041), the Deutsche Forschungsgemeinschaft (DFG; HE 1446/4–1), the Spanish Ministry of Education and Science (SAF2005–01005), the ‘Fondo de Investigaciones Sanitarias de la Seguridad Social, FIS (PI040632; PI081714), the Department of Health (Generalitat de Catalunya), CIBER is an initiative of ISCIII (Spain), the Department of Universities, Research and Information Society (2005SGR00008; 2009SGR 1554) (Generalitat de Catalunya), the Company of San Paolo (Grant No. 2007.0992 awarded to B. Nacmias), the University of Florence (Indagine genetica e studio dei fattori di rischio associati ai disturbi del comportamento alimentare : NACMATEN09), and by the Hilda and Preston Davis Foundation – Davis Foundation Postdoctoral Fellowship Program in Eating Disorders. The KORA research platform was initiated and financed by the Helmholtz Center Munich, German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. We thank all patients for their participation. The skillful technical assistance of Jitka Andrae and Sieglinde Düerkop is highly appreciated.
The authors declare that there is no conflict of interest.
Dr. Anke Hinney
Department of Child and Adolescent Psychiatry and Psychotherapy
University of Duisburg-Essen
Virchowstraße 174, 45147 Essen (Germany)
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.